Condition: EGFR-Mutant Non-Small Cell Lung Cancer · Sponsor: Voronoi, Inc
This first-in-human, Phase 1/2, multicenter, open-label, non-randomized study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of VRN110755, a highly selective oral epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR-mutant non-small cell lung cancer (NSCLC). The study includes a Phase 1a dose-escalation portion, a Phase 1b dose-expansion portion, and a Phase 2 evaluation. The study is designed to determine the maximum tolerated dose and recommended Phase 2 dose of VRN110755 and to evaluate preliminary and confirmatory antitumor activity in patients with EGFR-mutant NSCLC, including patients with acquired resistance following EGFR tyrosine kinase inhibitor therapy.
This description comes directly from the study's public registry record.
Somi Lee · 00 82 32 219 7849 · somi@voronoi.io
Always discuss trial participation with your own doctor first.
| Southern Oncology Clinical Research Unit | Bedford Park, South Australia, Australia | Recruiting |
| Monash Medical Centre Clayton | Clayton, Victoria, Australia | Recruiting |
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
| AP-HM Hôpital Nord | Marseille, Bouches-du-Rhône, France | Recruiting |
| Centre Georges François Leclerc | Dijon, Côte-d'Or, France | Recruiting |
| Prince of Wales Hospital | Hong Kong, Hong Kong | Recruiting |
| Queen Mary Hospital | Hong Kong, Hong Kong | Recruiting |
| Hospital Umum Sarawak | Kuching, Sarawak, Malaysia | Recruiting |
| Hospital Kuala Lumpur | Kuala Lumpur, Malaysia | Recruiting |
| University Malaya Medical Centre | Kuala Lumpur, Malaysia | Recruiting |
| Institut Kanser Negara | Putrajaya, Malaysia | Recruiting |
| National Cancer Centre Singapore | Singapore, Singapore | Recruiting |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07699328